Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201712-01 Development of a novel antipsychotic(CNS Diseases, Chemical) [2019-02-22]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

The goal of the present project is to obtain a phase 2 IND approval after successful completion of non-clinical and clinical studies and the ultimate goal is to globally develop a drug product treating schizophrenia through co-development or co-commercialization with global pharmaceutical companies.

Unmet Medical Need & Target Patients

1) Unmet Medical Needs

① Needs to develop drugs for patients with refractory positive symptoms and to overcome the limited efficacy of the present dopamine-based drugs

② Needs to develop drugs that are effective in negative symptoms which are present in nearly 50% of schizophrenia patients

③ Need to develop drugs that mitigate metabolic side-effects caused by the currently marked drugs and to improve patients’ non-compliance

2) Target Patients: Patients with positive and/or negative symptoms

Status

Domestic phase 1 clinical trial is in progress

Intellectual Property

The patent for the compound was granted in US and patent applications are pending in other countries. The patent expires in 2036.

Competitive Advantages

① Having a new mode of action of a non-dopaminergic drug as an antipsychotic and the possibility of expansion of indications to other psychiatric or neurological disorders

② No possibility of drug mechanism associated neurotoxicity as determined by the previous studies.

③ High possibility in fulfilling unmet needs of schizophrenia as confirmed to have the treatment effects of positive and negative symptoms of schizophrenia in animal models

Contact & Company Overview

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code